KR20220165003A - Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract - Google Patents
Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract Download PDFInfo
- Publication number
- KR20220165003A KR20220165003A KR1020210073409A KR20210073409A KR20220165003A KR 20220165003 A KR20220165003 A KR 20220165003A KR 1020210073409 A KR1020210073409 A KR 1020210073409A KR 20210073409 A KR20210073409 A KR 20210073409A KR 20220165003 A KR20220165003 A KR 20220165003A
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- acid
- hair loss
- preventing hair
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 239000002537 cosmetic Substances 0.000 title claims abstract description 28
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 22
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract description 21
- 239000000194 fatty acid Substances 0.000 title abstract description 21
- 229930195729 fatty acid Natural products 0.000 title abstract description 21
- 150000004665 fatty acids Chemical class 0.000 title abstract description 18
- 240000003065 Malva verticillata Species 0.000 title abstract description 5
- 235000002384 Malva verticillata Nutrition 0.000 title abstract description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 64
- 230000000694 effects Effects 0.000 claims abstract description 34
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 32
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 32
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000005642 Oleic acid Substances 0.000 claims abstract description 32
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 32
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 32
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 32
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 32
- 235000021313 oleic acid Nutrition 0.000 claims abstract description 31
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 24
- 230000003779 hair growth Effects 0.000 claims abstract description 18
- 230000002500 effect on skin Effects 0.000 claims abstract description 16
- 102000015735 Beta-catenin Human genes 0.000 claims abstract description 14
- 108060000903 Beta-catenin Proteins 0.000 claims abstract description 14
- 230000004663 cell proliferation Effects 0.000 claims abstract description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 230000001965 increasing effect Effects 0.000 claims abstract description 8
- 230000011664 signaling Effects 0.000 claims abstract description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 201000004384 Alopecia Diseases 0.000 description 13
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 12
- 230000003676 hair loss Effects 0.000 description 12
- 208000024963 hair loss Diseases 0.000 description 12
- 235000020778 linoleic acid Nutrition 0.000 description 12
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- -1 for example Substances 0.000 description 10
- 210000004209 hair Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 229960003632 minoxidil Drugs 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000002453 shampoo Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 229960004039 finasteride Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- KYYWBEYKBLQSFW-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O KYYWBEYKBLQSFW-UHFFFAOYSA-N 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940116335 lauramide Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Abstract
Description
본 발명은 동규자(Malva verticillata L.) 추출물에서 분리된 지방산을 유효성분으로 함유하는 탈모 방지용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for preventing hair loss containing, as an active ingredient, a fatty acid isolated from a Malva verticillata L. extract.
일반적으로 모발의 기능은 두피를 보호하고 체온을 유지하는 등의 외부 자극으로부터 인체 보호의 역할을 한다. 인체의 모발은 약 10만~15만 개 정도이며 모낭에서 형성된다. 각각의 모발은 서로 다른 주기를 가지며 성장기, 퇴행기, 휴지기를 거쳐서 성장하고 탈락한다. 이러한 주기는 3~6년에 걸쳐 반복되는데, 일일 평균 50~100개의 모발이 정상적으로 탈락하게 된다.In general, the function of hair serves to protect the human body from external stimuli such as protecting the scalp and maintaining body temperature. Human hair is about 100,000 to 150,000, and it is formed in the hair follicle. Each hair has a different cycle and grows and falls out through a growth phase, a regression phase, and a resting phase. This cycle is repeated over 3 to 6 years, and an average of 50 to 100 hairs per day are normally lost.
헤어 사이클은 호르몬, 스트레스, 질병, 환경오염, 흡연 등의 내·외적인 요인에 의해 변형 및 단축되며, 주기의 변화는 성장기 단계의 단축 및 초기 퇴화기 단계 진입, 휴지기 단계의 연장 등의 형태로 나타나게 된다. The hair cycle is transformed and shortened by internal and external factors such as hormones, stress, disease, environmental pollution, and smoking. do.
탈모증은 이러한 주기 중에서 성장기 모발의 비율이 짧아지고 퇴행기 또는 휴지기 모발이 많아져 탈락하는 모발의 숫자가 비정상적으로 많아지는 것을 말하며 100개 이상의 모발이 빠지는 경우에 탈모 증상을 의심할 수 있다.Alopecia refers to an abnormally large number of hairs falling out due to a shortened growth period hair ratio and an increase in catagen or telogen hairs during this cycle, and hair loss symptoms can be suspected when more than 100 hairs fall out.
임상학적으로 탈모는 흉터가 형성되는 탈모와 흉터가 형성되지 않는 탈모로 분류되며, 다양한 원인에 의해 발생되지만 유전적인 원인과 남성 호르몬인 테스토스테론이 중요한 인자로 여겨진다.Clinically, hair loss is classified into scar-forming hair loss and non-scarring hair loss, and although it is caused by various causes, genetic causes and male hormone testosterone are considered important factors.
테스토스테론은 골격근증가, 남성외부생식기, 음낭 성장, 정자 형성 등에 관여하며, 테스토스테론은 환원효소에 의해 디하이드로테스토스테론으로 환원되어 탈모, 여드름, 전립성 비대증에 관여하는 것으로 알려져 있다.(Diane et al; JID 775-778, 1995. Bruchovsky, Net al; JBC 243,2112~2121, 1968).Testosterone is involved in skeletal muscle growth, male external genitalia, scrotum growth, spermatogenesis, etc. Testosterone is reduced to dihydrotestosterone by a reductase and is known to be involved in hair loss, acne, and prostate enlargement. (Diane et al; JID 775 -778, 1995. Bruchovsky, Net al; JBC 243,2112-2121, 1968).
보다 자세하게는 디하이드로테스토스테론은 모낭 주변의 단백질 합성을 저하함으로써 모낭세포의 증식을 감소시켜 탈모를 유발하는 것으로 알려져 있다.More specifically, dihydrotestosterone is known to induce hair loss by reducing the proliferation of hair follicle cells by lowering protein synthesis around hair follicles.
현재까지 탈모방지 또는 육모촉진에 효과가 있다고 알려진 치료법은 미녹시딜(minoxidil) 용액의 도포나 트리코사카라이드(trichosaccharide)의 복용 등이 있다. 미녹시딜은 고혈압 치료를 위한 혈관확장제로 개발되었으나, 부작용으로 다모증이 보고되면서 발모제로 개발되었다. 미녹시딜의 발모효과에 대한 작용기전은 아직까지 명확히 밝혀지지 않았으나, 혈관확장을 통한 영양공급의 증가로 모발성장이 유도된다고 판단된다. 또한, 피나스테라이드(finasteride)는 남성호르몬 대사에 작용하는 효소인 5 알파-리덕타아제의 활성을 억제시키는 물질로서 처음에는 전립선 비대증 치료제로 개발되었으나, 부작용으로 다모증이 보고되면서 발모제로 개발되었다.Until now, treatments known to be effective in preventing hair loss or promoting hair growth include applying a minoxidil solution or taking trichosaccharide. Minoxidil was developed as a vasodilator for the treatment of hypertension, but as hirsutism was reported as a side effect, it was developed as a hair growth agent. Although the mechanism of action for the hair growth effect of minoxidil has not yet been clearly identified, it is believed that hair growth is induced by an increase in nutrient supply through vasodilation. In addition, finasteride (finasteride) is a substance that inhibits the activity of 5 alpha-reductase, an enzyme that acts on male hormone metabolism, and was initially developed as a treatment for prostatic hyperplasia, but was developed as a hair growth agent as hirsutism was reported as a side effect.
그러나, 미녹시딜과 피나스테라이드는 사용을 중단하면 효과가 사라지기 때문에 지속적으로 사용해야한다는 불편함이 있으며, 미녹시딜의 경우 끈적이는 사용감과 피부 자극이라는 부작용이 보고 되고, 피나스테라이드의 경우 정력감퇴, 발기부전 등의 성기능 장애가 보고되어 지속적인 사용에 제한이 따르는 실정이다.However, minoxidil and finasteride are inconvenient to continue to use because the effect disappears when use is stopped. In case of minoxidil, side effects such as sticky feeling and skin irritation have been reported, and in case of finasteride, sexual dysfunction such as energy loss and erectile dysfunction It has been reported that there are restrictions on continuous use.
대한민국 등록특허 제10-131097호는 탈모방지용 한방추출물 및 이를 포함하는 헤어용품 조성물에 대해 개시하고 있다. 대한민국 등록특허 제10-121834호는 동규자 등의 식물 추출물 또는 분획물을 함유하는 조성물, 그의 용도 및 상기 추출물의 제조방법에 대해 개시하고 있다.Korean Patent Registration No. 10-131097 discloses an herbal extract for preventing hair loss and a hair product composition containing the same. Republic of Korea Patent Registration No. 10-121834 discloses a composition containing a plant extract or fraction such as Donggyuja, its use, and a method for preparing the extract.
본 발명의 목적은 탈모완화 및 발모 촉진을 위해 천연 식물 및 이의 추출물에 대한 다양한 피부 생리활성을 검색한 결과, 동규자(Malva verticillata L.) 추출물로부터 분리한 지방산에서 탈모완화와 관련한 모유두세포 증식 효과, 세포의 모발 증식 신호전달(β-catenin level, VEGF, IGF-1) 효과를 확인함으로써 본 발명을 완성하였다.An object of the present invention is to search for various skin physiological activities of natural plants and extracts thereof for hair loss relief and hair growth promotion, and as a result, the fatty acid isolated from the Malva verticillata L. extract has a dermal papilla cell proliferation effect related to hair loss relief, The present invention was completed by confirming the effect of cellular hair growth signaling (β-catenin level, VEGF, IGF-1).
상기한 과제는, 동규자 추출물로부터 분리된 지방산인 리놀레산, 올레산 및 팔미트산을 유효성분으로 포함하는 탈모 방지용 화장료 조성물에 의해 달성된다. The above object is achieved by a cosmetic composition for preventing hair loss comprising linoleic acid, oleic acid and palmitic acid, which are fatty acids isolated from the extract of Donggyuja, as active ingredients.
바람직하게는, 상기 화장료 조성물은 화장료 조성물 총 중량 대비 리놀레산 0.5 내지 2.5 중량 %, 올레산 0.5 내지 1.5 중량% 및 팔미트산 0.5 내지 1.5 중량%를 함유할 수 있다.Preferably, the cosmetic composition may contain 0.5 to 2.5% by weight of linoleic acid, 0.5 to 1.5% by weight of oleic acid, and 0.5 to 1.5% by weight of palmitic acid based on the total weight of the cosmetic composition.
또한 바람직하게는, 상기 리놀레산, 올레산 및 팔미트산는 2:1:1의 중량비로 혼합되어 포함될 수 있다.Also preferably, the linoleic acid, oleic acid and palmitic acid may be mixed in a weight ratio of 2:1:1.
또한 바람직하게는, 상기 화장료 조성물은 모유두세포 증식 효과, 세포의 모발 증식 신호전달(VEGF, IGF-1) 조절 효과 또는 β-카테닌(β-catenin) 발현 증가 효과를 갖는다.Also preferably, the cosmetic composition has a dermal papilla cell proliferation effect, a cell hair growth signaling (VEGF, IGF-1) regulatory effect or an effect of increasing β-catenin (β-catenin) expression.
본 발명의 화장료 조성물은 동규자 추출물부터 분리된 지방산을 유효성분으로 포함하하여 탈모를 방지하는 효과를 갖는다. 상기 탈모 방지용 화장료 조성물은 모유두세포 증식 효과, 세포의 모발 증식 신호전달(β-catenin level, VEGF, IGF-1) 조절 효과를 가진다.The cosmetic composition of the present invention contains the fatty acid isolated from the extract of Donggyuja as an active ingredient and has an effect of preventing hair loss. The cosmetic composition for preventing hair loss has a dermal papilla cell proliferation effect and a cell hair growth signaling (β-catenin level, VEGF, IGF-1) regulation effect.
도 1은 동규자 추출물의 메틸렌클로라이드 분획물에 분리한 리놀레산, 올레산, 팔미트산을 고속액체크로마토그라피를 이용하여 분석한 것이다.
도 2는 제조예 1의 동규자 추출물과, 제조예 3~18의 리놀레산, 올레산 및 팔미트산 각각 또는 혼합물의 모유두 세포 증식율을 나타낸 것이다.
도 3 및 도 4는 제조예 1의 동규자 추출물과, 제조예 3~18의 리놀레산, 올레산 및 팔미트산 각각 또는 혼합물의 모발 성장인자(IGF-1, VEGF) 발현 촉진 효과를 나타낸 것이다.
도 5는 제조예 1의 동규자 추출물과, 제조예 3~18의 리놀레산, 올레산 및 팔미트산 각각 또는 혼합물의 β-카테닌 발현 촉진 효과를 나타낸 것이다.1 is an analysis of linoleic acid, oleic acid, and palmitic acid separated from the methylene chloride fraction of Donggyuja extract using high performance liquid chromatography.
Figure 2 shows the dermal papilla cell proliferation rate of the Donggyuja extract of Preparation Example 1 and each or mixture of linoleic acid, oleic acid and palmitic acid in Preparation Examples 3 to 18.
Figures 3 and 4 show the hair growth factor (IGF-1, VEGF) expression promoting effect of the Donggyuja extract of Preparation Example 1 and each or mixture of linoleic acid, oleic acid and palmitic acid of Preparation Examples 3 to 18.
Figure 5 shows the β-catenin expression promoting effect of Donggyuja extract of Preparation Example 1 and each or mixture of linoleic acid, oleic acid and palmitic acid of Preparation Examples 3 to 18.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 하기의 정의를 가지며 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미에 부합된다. 또한 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다.All technical terms used in the present invention, unless otherwise defined, have the following definitions and correspond to the meanings commonly understood by those of ordinary skill in the art related to the present invention. In addition, although preferred methods or samples are described in this specification, those similar or equivalent thereto are also included in the scope of the present invention.
용어 "약"이라는 것은 참조 양, 수준, 값, 수, 빈도, 퍼센트, 치수, 크기, 양, 중량 또는 길이에 대해 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 또는 1% 정도로 변하는 양, 수준, 값, 수, 빈도, 퍼센트, 치수, 크기, 양, 중량 또는 길이를 의미한다.The term "about" means a reference amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length of 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, means an amount, level, value, number, frequency, percentage, dimension, size, quantity, weight or length that varies by 4, 3, 2 or 1%.
본 명세서를 통해, 문맥에서 달리 필요하지 않으면, "포함하다" 및 "포함하는"이란 말은 제시된 단계 또는 구성요소, 또는 단계 또는 구성요소들의 군을 포함하나, 임의의 다른 단계 또는 구성요소, 또는 단계 또는 구성요소들의 군이 배제되지는 않음을 내포하는 것으로 이해하여야 한다.Throughout this specification, unless the context requires otherwise, the terms "comprise" and "comprising" include a given step or element, or group of steps or elements, but any other step or element, or It is to be understood that steps or groups of components are not excluded.
본 발명은 동규자 추출물부터 분리된 지방산, 특히 리놀레산, 올레산, 팔미트산을 유효 성분으로 포함하는 탈모 방지용 화장료 조성물에 대한 것이다.The present invention relates to a cosmetic composition for preventing hair loss comprising fatty acids, particularly linoleic acid, oleic acid, and palmitic acid isolated from an extract of Donggyuja, as an active ingredient.
본 발명에 사용된 동규자는 아욱과에 속하는 1년생 초본 식물, 아욱의 씨앗으로써, 북부온대 및 아열대 기후에 주로 자생하며, 우리나라 각지에서 자생한다. 우리나라에서는 오래 전부터 재배하여 식용 채소로써 이용되어져 왔으며, 종자인 동규자는 규자, 규채자 등의 이명으로 예로부터 이뇨, 활장, 하유, 해독 등의 효능이 알려져 있다.Donggyuja used in the present invention is a seed of mallow, an annual herbaceous plant belonging to the Malvaceae family, and grows naturally in northern temperate and subtropical climates, and grows wild in various parts of Korea. In Korea, it has been cultivated and used as an edible vegetable for a long time. Donggyuja, which is a seed, has been known for its diuretic, sluggish, oily, and detoxifying effects.
본 발명의 동규자 추출물로부터 분리된 지방산은 포화되거나 불포화된 긴 지방족 사슬을 가진 카복실산이다. 지방산은 일반적으로 생물에 존재하며, 동물의 에너지원이나 세포에서 중요한 구조적 구성 성분으로 사용된다. 지방산은 사슬의 길이나 불포화 탄소 개수에 따라 분류된다. 일반적으로 알려진 포화지방산에는 미리스트산, 팔미트산, 스테아르산 등이 있으며, 불포화지방산에는 미리스톨레산, 올레산, 리놀레산, 리놀렌산 등이 있다.The fatty acids isolated from the extract of Donggyuja of the present invention are saturated or unsaturated carboxylic acids with long aliphatic chains. Fatty acids are generally present in living organisms and are used as energy sources in animals or as important structural components in cells. Fatty acids are classified according to chain length or number of unsaturated carbon atoms. Commonly known saturated fatty acids include myristic acid, palmitic acid, and stearic acid, and unsaturated fatty acids include myristic acid, oleic acid, linoleic acid, and linolenic acid.
상기 동규자 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건하에서, 통상적인 용매를 사용하여 제조될 수 있으나, 바람직하게는 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 용매를 이용한 용매 추출법, (b) 이산화탄소에 의한 감압 및 고온에 의한 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한다. The Donggyuja extract may be prepared according to a conventional method known in the art, that is, under conventional temperature and pressure conditions, using a conventional solvent, but preferably (a) water and 1-4 carbon atoms. Anhydrous or hydrous lower alcohols (e.g. methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane Extraction is performed using a solvent extraction method using a solvent selected from the group consisting of and mixtures thereof, (b) supercritical extraction method using carbon dioxide under reduced pressure and high temperature, or (c) ultrasonic extraction method.
본 발명에서는 바람직하게는 추출용매를 이용한 용매 추출법을 이용하였다. 본 발명에서 동규자 추출물은 다양한 추출용매, 예를 들어, 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 1종 이상의 추출 용매를 사용하여 얻을 수 있으며, 바람직하게는 에탄올, 70%(v/v) 에탄올 또는 물을 사용하여 얻어진 것이고, 가장 바람직하게는 70%(v/v) 에탄올을 사용하여 얻어진 것이다.In the present invention, a solvent extraction method using an extraction solvent is preferably used. In the present invention, Donggyuja extract is prepared by using various extraction solvents, for example, water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (eg, methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol , It can be obtained using one or more extraction solvents selected from the group consisting of glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane, and mixtures thereof, preferably ethanol, 70% (v/v) ethanol or water, most preferably 70% (v/v) ethanol.
한편, 본 발명의 동규자 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다. 또한, 본 발명의 동규자 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 및 발효 과정을 거친 추출물도 포함한다. 예컨대, 이산화탄소에 의한 감압, 고온에 의한 초임계추출법에 의한 추출, 초음파를 이용한 추출법에 의한 추출, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 유기용매를 이용한 분획물, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리하거나 자연 상태나 각종 미생물을 이용한 발효산물에 의한 추출물 등, 추가적으로 실시된 다양한 정제 및 추출방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함된다.On the other hand, it is obvious to those skilled in the art that the extract of Donggyuja of the present invention can be obtained using not only the above extraction solvent but also other extraction solvents that exhibit substantially the same effect. In addition, the extract of Donggyuja of the present invention includes not only the extract using the above-described extraction solvent, but also an extract that has undergone conventional purification and fermentation processes. For example, decompression by carbon dioxide, extraction by supercritical extraction by high temperature, extraction by ultrasonic extraction, separation using an ultrafiltration membrane with a constant molecular weight cut-off value, fractionation using an organic solvent, various chromatography (size , charge, hydrophobicity, or affinity), or the active fraction obtained through various additional purification and extraction methods, such as extraction by fermentation products using natural conditions or various microorganisms, are also of the present invention. included in the extract.
상기 추출물의 분획물은 헥산, 메틸렌클로라이드, 에틸아세테이트 및 부탄올로 이루어진 군으로부터 선택된 어느 하나의 유기용매를 가하여 수득한 것일 수 있고, 보다 구체적으로 메틸렌클로라이드을 가하여 수득한 것일 수 있다.The fraction of the extract may be obtained by adding any one organic solvent selected from the group consisting of hexane, methylene chloride, ethyl acetate and butanol, and more specifically, may be obtained by adding methylene chloride.
본 발명의 구체예에서, 동규자 추출물로부터 얻어진 헥산 분획물, 메틸렌클로라이드 분획물, 에틸아세테이트 분획물, 부탄올 분획물이 모유두세포 증식에 활성을 나타내어 우수한 탈모완화 효과를 나타냄을 확인하였으며, 메틸렌클로라이드 분획물의 탈모완화 효과가 보다 우수함을 확인하였다.In a specific embodiment of the present invention, it was confirmed that the hexane fraction, the methylene chloride fraction, the ethyl acetate fraction, and the butanol fraction obtained from the Donggyuja extract exhibited an excellent hair loss alleviating effect by exhibiting activity in dermal papilla cell proliferation, and the methylene chloride fraction had a hair loss alleviating effect It was confirmed that it is better.
본 발명의 일 실시형태에 따르면, 상기 동규자 추출물로부터 분리된 지방산은 상기 동규자 추출물의 메틸렌클로라이드 분획물로부터 분리된 리놀레산, 올레산 및 팔미트산을 포함할 수 있다. 구체적으로 상기 동규자 추출물로부터 분리된 지방산은 리놀레산, 올레산, 팔미트산을 말하며, 상기 지방산은 화장료 조성물 총 중량 대비 0.01중량% 내지 10중량%로 함유될 수 있다.According to one embodiment of the present invention, the fatty acid isolated from the extract of Donggyuja may include linoleic acid, oleic acid and palmitic acid isolated from the methylene chloride fraction of the extract of Donggyuja. Specifically, the fatty acids isolated from the Donggyuja extract refer to linoleic acid, oleic acid, and palmitic acid, and the fatty acids may be contained in an amount of 0.01% to 10% by weight based on the total weight of the cosmetic composition.
상기 리놀레산은 하기 화학식 1로 표시되는 구조를 가진다.The linoleic acid has a structure represented by Formula 1 below.
[화학식 1][Formula 1]
상기 올레산은 하기 화학식 2로 표시되는 구조를 가진다.The oleic acid has a structure represented by Formula 2 below.
[화학식 2][Formula 2]
상기 팔미트산은 하기 화학식 3으로 표시되는 구조를 가진다.The palmitic acid has a structure represented by Formula 3 below.
[화학식 3][Formula 3]
바람직하게는, 본 발명에 따른 화장료 조성물은, 화장료 조성물 총 중량 대비 리놀레산을 0.5 중량% 내지 2.5 중량%, 올레산을 0.5 중량% 내지 2.5 중량%, 팔미트산을 0.5 중량% 내지 2.5 중량%로 함유할 수 있다. 보다 바람직하게는, 리놀레산 0.5 내지 2.5 중량 %, 올레산 0.5 내지 1.5 중량% 및 팔미트산 0.5 내지 1.5 중량%를 함유될 수 있다. Preferably, the cosmetic composition according to the present invention contains 0.5% to 2.5% by weight of linoleic acid, 0.5% to 2.5% by weight of oleic acid, and 0.5% to 2.5% by weight of palmitic acid, based on the total weight of the cosmetic composition. can do. More preferably, it may contain 0.5 to 2.5% by weight of linoleic acid, 0.5 to 1.5% by weight of oleic acid and 0.5 to 1.5% by weight of palmitic acid.
본 발명의 일 실시형태에 따르면, 상기 리놀레산, 올레산 및 팔미트산는 2:1:1의 중량비로 혼합되어 포함될 수 있다.According to one embodiment of the present invention, the linoleic acid, oleic acid and palmitic acid may be mixed in a weight ratio of 2:1:1.
본 발명에 따른 화장료 조성물은 동규자 추출물에 분리된 리놀레산, 올레산 및 팔미트산를 포함하여, 모유두세포 증식 효과, 세포의 모발 증식 신호전달(VEGF, IGF-1) 조절 효과 또는 β-카테닌(β-catenin) 발현 증가 효과를 갖는다.The cosmetic composition according to the present invention includes linoleic acid, oleic acid, and palmitic acid separated from the extract of Donggyuja, and has a dermal papilla cell proliferation effect, a cell hair growth signaling (VEGF, IGF-1) regulatory effect, or β-catenin (β-catenin). ) has an effect of increasing expression.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서 상기 유효 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.Ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions in addition to the active ingredients as active ingredients, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances. adjuvants, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 팩, 마사지크림 및 스프레이 등으로 제형화 될 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition of the present invention can be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , It may be formulated as an oil, pack, massage cream and spray, etc., but is not limited thereto.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 샴푸 제형 또는 계면활성제 비함유 샴푸 제형일 경우, 모발과 두피에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, surfactant-containing shampoo formulation, or surfactant-free shampoo formulation, it may be applied to the hair and scalp and then wiped off, removed, or washed with water. As specific examples, the soap is liquid soap, powder soap, solid soap, and oil soap, and the surfactant-free cleansing formulation includes, but is not limited to, a cleansing cream, a cleansing lotion, a cleansing water, and a cleansing gel.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and the scope of the present invention is not limited by these examples according to the gist of the present invention.
제조예 1: 동규자 추출물 제조Preparation Example 1: Preparation of Donggyuja Extract
동규자 10kg을 깨끗한 물로 씻어 건조시킨 다음 일정한 크기(100mesh)로 분쇄하여 70%(V/V) 에탄올 수용액으로 5시간씩 3회 환류 추출하고 냉침한 후, 와트만(Whatman) #4 여과지로 여과하여 농축기를 이용하여 동규자 추출물 1.2kg을 제조하였다.After washing 10kg of same-gyuja with clean water and drying it, it was pulverized into a certain size (100mesh), extracted with 70% (V/V) ethanol aqueous solution under reflux three times for 5 hours each, cooled, and filtered with Whatman #4 filter paper. 1.2 kg of Donggyuja extract was prepared using a concentrator.
제조예 2: 동규자 추출물의 메틸렌클로라이드 분획물 및 지방산의 분리Preparation Example 2: Separation of Methylene Chloride Fraction and Fatty Acids of Donggyuja Extract
상기 제조예1에서 얻은 동규자 추출물 0.6kg을 헥산과 메틸렌클로라이드, 에틸아세테이트 및 부탄올을 이용하여 통상적인 방법으로 순차적으로 용매분획을 실시한 후 감압농축하여 헥산 분획물 21.2g, 메틸렌클로라이드 분획물 13.2g, 에틸아세테이트 분획물 12.4g, 부탄올 분획물 8.2g을 수득하였다.0.6 kg of Donggyuja extract obtained in Preparation Example 1 was sequentially subjected to solvent fractionation in a conventional manner using hexane, methylene chloride, ethyl acetate and butanol, and then concentrated under reduced pressure to obtain 21.2 g of hexane fraction, 13.2 g of methylene chloride fraction, and ethyl acetate Fractions of 12.4 g and butanol fractions of 8.2 g were obtained.
상기에서 얻은 동규자 추출물의 메틸렌클로라이드 분획물을 8,000 rpm에서 15분 동안 원심분리하여 상등액을 취하였다. 이를 분취 고속액체크로마토그라피로 정제하여 리놀레산, 올레산, 팔미트산을 분리하였다. 리놀레산, 올레산, 팔미트산의 정성은 고속액체크로마토그라피를 이용하여 도 1에서 확인하였다.The methylene chloride fraction of the Donggyuja extract obtained above was centrifuged at 8,000 rpm for 15 minutes to obtain the supernatant. This was purified by preparative high-performance liquid chromatography to separate linoleic acid, oleic acid, and palmitic acid. The quality of linoleic acid, oleic acid, and palmitic acid was confirmed in FIG. 1 using high-performance liquid chromatography.
제조예 3 ~ 18: 동규자 추출물로부터 얻어진 리놀레산, 올레산, 팔미트산의 비율을 달리한 혼합물 제조Preparation Examples 3 to 18: Preparation of mixtures with different ratios of linoleic acid, oleic acid, and palmitic acid obtained from Donggyuja extract
상기 제조예 2에서 얻은 리놀레산, 올레산, 팔미트산의 탈모완화 효과를 확인하기 위하여 단일 지방산과 각 지방산의 혼합 비율을 달리한 혼합물을 제조하여 사용하였다. 동규자추출물의 제조예에 따른 리놀레산, 올레산, 팔미트산의 비율(%)는 하기 표 1에 표시하였다.In order to confirm the hair loss relief effect of linoleic acid, oleic acid, and palmitic acid obtained in Preparation Example 2, a mixture of a single fatty acid and each fatty acid at different mixing ratios was prepared and used. The ratio (%) of linoleic acid, oleic acid, and palmitic acid according to the preparation example of Donggyuja extract is shown in Table 1 below.
(Linoleic acid)(Linoleic acid)
(Oleic acid)(Oleic acid)
(Palmitic acid)(Palmitic acid)
(Linoleic acid)(Linoleic acid)
(Oleic acid)(Oleic acid)
(Palmitic acid)(Palmitic acid)
실험예 1: 모유두 세포 증식 평가Experimental Example 1: Evaluation of dermal papilla cell proliferation
인간 유래 모유두 세포(human follicle dermal papilla cells, HFDPC)를 1 × 104 cells/ml로 96 well plate에 분주하고, 37℃, 5% CO2 세포 배양기에서 24 시간 안정화시켰다. 이를 1% FBS를 함유한 DMEM 배지로 교환한 후 시료를 농도별로 희석하여 처리하고 48 시간 반응시켰다. 그 다음 5 mg/ml 농도의 MTT 시약을 각 well에 20 ㎕씩 첨가하고 37℃, 5% CO2 세포 배양기에서 2 ~ 3 시간 동안 반응시켰다. 반응이 끝난 각 well의 상층액을 모두 제거하고 DMSO 100 ㎕를 첨가하여 세포를 완전히 용해시킨 후 550 nm에서 흡광도를 측정하였다. 이때 양성 대조군은 모발성장촉진제제인 미녹시딜(minoxidil)을 사용하였으며, 대조군의 흡광도 값과 비교하여 각 시료군의 세포 증식율을 계산하여 도 2에 나타내었다.Human-derived dermal papilla cells (human follicle dermal papilla cells, HFDPC) were dispensed into a 96 well plate at 1 × 10 4 cells/ml, and stabilized for 24 hours in a 37°C, 5% CO 2 cell incubator. After exchanging it with a DMEM medium containing 1% FBS, the samples were diluted by concentration and reacted for 48 hours. Then, 20 μl of MTT reagent at a concentration of 5 mg/ml was added to each well and reacted for 2 to 3 hours in a 37° C., 5% CO 2 cell incubator. After the reaction was completed, the supernatant of each well was removed, and 100 μl of DMSO was added to completely dissolve the cells, and the absorbance was measured at 550 nm. At this time, the positive control group used minoxidil, a hair growth promoting agent, and compared with the absorbance value of the control group, the cell proliferation rate of each sample group was calculated and shown in FIG. 2 .
동규자 추출물 및 제조예 3~18에 대한 모유두 세포 증식 평가 실험 결과를 도 2에 도시하였다. 도 2에 도시되는 바와 같이, 제조예 1을 포함한 모든 제조예에서 모유두세포 증식 효과를 나타내었다. 특히 리놀레산 2 : 올레산1 : 팔미트산 1로 혼합한 제조예 9에서 모유두세포 증식율이 약 27% 증가함으로 가장 우수한 효과를 나타내었다.The results of the dermal papilla cell proliferation evaluation test results for the Donggyuja extract and Preparation Examples 3 to 18 are shown in FIG. 2 . As shown in Figure 2, the dermal papilla cell proliferation effect was shown in all preparation examples including preparation example 1. In particular, in Preparation Example 9 in which linoleic acid 2: oleic acid 1:
실험예 2: 모발 성장인자 발현 촉진 효과Experimental Example 2: Hair growth factor expression promotion effect
모유두세포를 1 × 105 cells/ml 농도로 96 well에 분주하고 37℃, 5% CO2 incubator에서 하루 동안 배양한 후 시료를 농도별로 처리하여 37℃, 5% CO2 incubator에서 24시간 반응시켰다. 세포의 배양액을 이용하여 효소면역측정법(ELISA; enzyme-linked immunosorbent assay)을 통해 측정하였다.Dermal papilla cells were dispensed into 96 wells at a concentration of 1 × 10 5 cells/ml and cultured for one day at 37°C, 5% CO 2 incubator, and then the samples were treated by concentration and reacted in a 37°C, 5% CO 2 incubator for 24 hours. . It was measured by enzyme-linked immunosorbent assay (ELISA) using the cell culture medium.
세포 배양액에서 IGF-1 (Insuline-like growth factor), VEGF (Vascular endothelial growth factor)의 발현을 ELISA kit를 이용하여 분석하였고, 450 nm에서 흡광도를 찍어 각각의 생성량을 도 3과 도 4에 나타내었다. 이때 양성 대조군은 모발성장촉진제제인 미녹시딜(minoxidil)을 사용하였다.The expression of IGF-1 (Insuline-like growth factor) and VEGF (Vascular endothelial growth factor) in the cell culture was analyzed using an ELISA kit, and the absorbance was taken at 450 nm, and the respective production amounts are shown in FIGS. 3 and 4 . At this time, the positive control group used minoxidil, a hair growth promoting agent.
도 3과 4에 도시되는 바와 같이 제조예 1 및 제조예 3~18에서 모발 성장인자 발현 촉진효과를 나타내었다.As shown in Figures 3 and 4, the hair growth factor expression promoting effect was shown in Preparation Example 1 and Preparation Examples 3 to 18.
특히 도 3에 도시되는 바와 같이, 리놀레산 1 : 올레산1 : 팔미트산 1로 혼합한 제조예 6과 리놀레산 2 : 올레산1 : 팔미트산 1로 혼합한 제조예 9에서 IGF-1 생성량이 각각 26%, 27% 증가함으로 가장 우수한 효과를 나타내었다.In particular, as shown in FIG. 3, in Preparation Example 6 in which linoleic acid 1 : oleic acid 1 :
또한 도 4에 도시되는 바와 같이, 리놀레산 2 : 올레산1 : 팔미트산 1로 혼합한 제조예 9에서 VEGF 생성량이 약 24%로 가장 많이 증가함을 확인하였다.In addition, as shown in FIG. 4, it was confirmed that the production of VEGF increased the most to about 24% in Preparation Example 9 in which linoleic acid 2: oleic acid 1:
실험예 3: Wnt/β-catenin 발현율 확인Experimental Example 3: Confirmation of Wnt/β-catenin expression rate
모유두세포를 2 × 105 cells/well 농도로 6 well에 분주하고 37℃, 5% CO2 incubator에서 하루 동안 배양한 후, 시료를 농도별로 처리하여 24시간 동안 배양하였다. 배양된 세포를 수거하여 용해시키고 BCA assay를 이용하여 단백질을 정량하였다. 정량한 단백질은 10% SDS-PAGE gel에서 전기영동 시킨 후 PVDF 멤브레인에 전이시켰다. 1차 항체(β-catenin, santa cruz, USA)를 4℃에서 오버나이트로 shaking 처리한 후, HRP가 결합된 2차 항체를 실온에서 2 시간 반응시켰다. 그 후, 1 × TBST로 3 번 세척하고 ECL 반응 kit를 이용하여 밴드를 확인하였다.Dermal papilla cells were dispensed into 6 wells at a concentration of 2 × 10 5 cells/well and cultured in a 37°C, 5% CO 2 incubator for one day, and then the samples were treated by concentration and cultured for 24 hours. The cultured cells were collected and lysed, and proteins were quantified using BCA assay. The quantified proteins were electrophoresed on a 10% SDS-PAGE gel and then transferred to a PVDF membrane. After shaking the primary antibody (β-catenin, santa cruz, USA) overnight at 4°C, the HRP-conjugated secondary antibody was reacted at room temperature for 2 hours. After that, it was washed three times with 1 × TBST and the band was confirmed using an ECL reaction kit.
각 밴드의 강도(intensity)는 β-actin의 발현을 기준으로 정량하여 β-catenin 발현율을 계산하였으며, 이때 양성 대조군은 모발성장촉진제제인 미녹시딜(minoxidil)을 사용하여 도 5에 도시하였다.The intensity of each band was quantified based on the expression of β-actin to calculate the β-catenin expression rate. At this time, the positive control was shown in FIG. 5 using minoxidil, a hair growth promoter.
도 3에 도시되는 바와 같이, 제조예 1 및 제조예 3~18에서 β-actin의 발현을 촉진하였다. 특히 리놀레산 1 : 올레산 1 : 팔미트산 1로 혼합한 제조예 6과 리놀레산 2 : 올레산 1 : 팔미트산 1로 혼합한 제조예 9에서 β-actin의 발현양이 각각 51%, 49% 증가함으로 가장 우수한 효과를 나타내었다.As shown in Figure 3, the expression of β-actin was promoted in Preparation Example 1 and Preparation Examples 3 to 18. In particular, in Preparation Example 6 mixed with linoleic acid 1: oleic acid 1:
제형예 1 ~ 2 : 동규자 추출물을 포함하는 탈모 방지용 샴푸의 제조Formulation Examples 1 to 2: Preparation of Shampoo for Preventing Hair Loss Containing Donggyuja Extract
본 발명에 따른 조성물의 제형예를 상기 제조예 1에서 수득한 동규자 추출물이 3 중량% 포함한 제형예 1과 상기 리놀레산 2 : 올레산 1 : 팔미트산 1로 혼합한 제조예 9를 3 중량% 포함한 제형예 2의 탈모 방지용 조성물은 하기 표의 조성으로 설명하였다. 이는 여러 가지 제형으로 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 한다.A formulation example of the composition according to the present invention containing 3% by weight of Preparation Example 1 containing 3% by weight of the Donggyuja extract obtained in Preparation Example 1 and Preparation Example 9 in which linoleic acid 2: oleic acid 1:
본 제형예 1과 2에서는 동규자 추출물을 포함하는 탈모 방지용 조성물로 아래 표 2의 함량에 따른 샴푸(shampoo)를 제조하였지만, 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이크림, 샴푸, 트리트먼트, 두피 앰플, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.In Formulation Examples 1 and 2, shampoos according to the contents of Table 2 below were prepared as compositions for preventing hair loss containing Donggyuja extract, but in more detail, softening lotion, nutrient lotion, nutrient cream, massage cream, essence, It may be formulated into an eye cream, shampoo, treatment, scalp ampoule, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
실험예 1 : 화장료의 탈모 방지 효과Experimental Example 1: Anti-hair loss effect of cosmetics
본 실험예 1에서는 상기 제형예에서 제조한 샴푸의 탈모 방지 효과를 확인하였다. 탈모 증세가 있다고 인식하는 성인 남성 20명을 무작위로 10명씩 2개 그룹(A, B)으로 나눈 뒤 실험군(A) 10명, 대조군(B) 10명으로 구성하여 4주 동안 실험을 진행하였다. A 그룹을 대상으로 제형예 1의 조성물을, B 그룹을 대상으로 제형예 2의 조성물을, C 그룹을 대상으로 비교예 1의 조성물을 각각 2일 간격으로 사용하여 그 결과를 관찰하였다. 탈모 방지의 정도는 실험 종료 후 피시험자들이 평가 기준(-3:매우 악화, -2:악화, -1:약간 악화, 0:변화 없음, 1:약간 개선, 2:개선, 3:매우 개선)에 따라 관능 평가하도록 하여 아래 표 3에 나타내었다.In Experimental Example 1, the hair loss prevention effect of the shampoo prepared in the formulation example was confirmed. After randomly dividing 20 adult males who recognized that they had hair loss into 2 groups (A, B) of 10 people each, the experiment was conducted for 4 weeks with 10 people in the experimental group (A) and 10 people in the control group (B). The composition of Formulation Example 1 was used for Group A, the composition of Formulation Example 2 was used for Group B, and the composition of Comparative Example 1 was used for Group C at 2-day intervals, respectively, and the results were observed. The degree of hair loss prevention was evaluated by the test subjects after the experiment was completed (-3: very worse, -2: worse, -1: slightly worse, 0: no change, 1: slightly improved, 2: improved, 3: very improved) According to the sensory evaluation, it is shown in Table 3 below.
상기 표 2에 나타난 바와 같이, 제형예 2의 조성물이 비교예 1의 조성물에 비하여 탈모 방지 효과가 뛰어난 것으로 나타났다.As shown in Table 2, the composition of Formulation Example 2 was found to have an excellent hair loss prevention effect compared to the composition of Comparative Example 1.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210073409A KR102491505B1 (en) | 2021-06-07 | 2021-06-07 | Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210073409A KR102491505B1 (en) | 2021-06-07 | 2021-06-07 | Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220165003A true KR20220165003A (en) | 2022-12-14 |
KR102491505B1 KR102491505B1 (en) | 2023-01-26 |
Family
ID=84438367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210073409A KR102491505B1 (en) | 2021-06-07 | 2021-06-07 | Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102491505B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0959127A (en) * | 1995-08-10 | 1997-03-04 | Mikimoto Pharmaceut Co Ltd | Food product and cosmetic containing solvent extract from malva verticillata |
KR20120128474A (en) * | 2011-05-17 | 2012-11-27 | 차의과학대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth comprising Malvae Fructus extracts or compounds isolated therefrom |
KR20170005952A (en) * | 2015-07-06 | 2017-01-17 | 코스맥스 주식회사 | Cosmetic composition comprising Malva verticillata Seed extract for prevention of skin aging or anti-wrinkles |
KR20200072108A (en) * | 2018-12-12 | 2020-06-22 | 주식회사 코리아나화장품 | Cosmetic Composition For Preventing Hair Loss Containing Malva verticillata L. Seed Extract |
KR102165210B1 (en) * | 2019-11-27 | 2020-10-15 | 주식회사 코씨드바이오팜 | Cosmetic composition for preventing hair loss with Malva verticillata L. Seed Extract |
-
2021
- 2021-06-07 KR KR1020210073409A patent/KR102491505B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0959127A (en) * | 1995-08-10 | 1997-03-04 | Mikimoto Pharmaceut Co Ltd | Food product and cosmetic containing solvent extract from malva verticillata |
KR20120128474A (en) * | 2011-05-17 | 2012-11-27 | 차의과학대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth comprising Malvae Fructus extracts or compounds isolated therefrom |
KR20170005952A (en) * | 2015-07-06 | 2017-01-17 | 코스맥스 주식회사 | Cosmetic composition comprising Malva verticillata Seed extract for prevention of skin aging or anti-wrinkles |
KR20200072108A (en) * | 2018-12-12 | 2020-06-22 | 주식회사 코리아나화장품 | Cosmetic Composition For Preventing Hair Loss Containing Malva verticillata L. Seed Extract |
KR102165210B1 (en) * | 2019-11-27 | 2020-10-15 | 주식회사 코씨드바이오팜 | Cosmetic composition for preventing hair loss with Malva verticillata L. Seed Extract |
Also Published As
Publication number | Publication date |
---|---|
KR102491505B1 (en) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7910557B2 (en) | Hair care product | |
KR102326641B1 (en) | Composition comprising extract of buckwheat sprout for strengthening hair root, activating hair growth or preventing alopecia | |
KR101322926B1 (en) | A Composition for prevention of hair loss and promotion of hair growth comprising extracts of Eclipta prostrata, fractions thereof, terthienyl derivatives or pharmaceutically acceptable salts thereof | |
KR102165210B1 (en) | Cosmetic composition for preventing hair loss with Malva verticillata L. Seed Extract | |
KR102107194B1 (en) | Cosmetic Composition For Preventing Hair Loss Containing Arctium Lappa Seed Extract | |
KR102491505B1 (en) | Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract | |
JP2007509133A (en) | Cosmetic composition for improving wrinkles containing a red wrinkle extract {CosmeticsComposingsExtractingFractionMallotusjaponicusforImprovingSkinWrinkle} | |
EP1861486A1 (en) | A process of preparing jambu extract, use of said extract, cosmetic compositions comprising thereof and cosmetic products comprising said cosmetic compositions | |
KR102213767B1 (en) | Cosmetic Composition For Preventing Hair Loss Containing Malva verticillata L. Seed Extract | |
KR101233910B1 (en) | Composition for Preventing Hair Loss or Promoting Hair Generation | |
KR102342503B1 (en) | Composition for anti-pruritic comprising mixture of luteolin and apigenin as effective component | |
JP3090156B2 (en) | Cosmetics | |
KR102257477B1 (en) | Cosmetic composition having Anti-pollution effect comprising Lotus leaf extracts as an effective component | |
KR20170110910A (en) | Hair growth activating composition comprising leaf extract of conifer containing pinane | |
KR102013803B1 (en) | A composition for improving alopecia containing novel compounds isolated from chestnut bur | |
EP3381441B1 (en) | External use skin composition for antiaging containing germinated glycine gracilis extract as active ingredient | |
KR102300364B1 (en) | Composition for promoting hair growth and/or restoration containing psoralidin | |
KR102174309B1 (en) | Cosmetic composition for prevention of losing hair or promotion of growing hair containing Taxillus yadoriki extract | |
JP6655296B2 (en) | Hair growth or hair growth promoter | |
KR102491296B1 (en) | Skin whitening cosmetic composition using pear peel | |
KR102276483B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Complex Extracts of Prunellae spica, Polygonum cuspidata, and Cnidium officinale as an Active Ingredient | |
KR102637563B1 (en) | Cosmetic composition for improving skin condition comprising extract of silene acaulis callus | |
KR20180099563A (en) | Cosmetic composition for improving skin wrinkle comprising Oxya chinensis sinuosa extract or compound isolated from the extract as effective component | |
KR102438389B1 (en) | Composition for preventing or improving skin wrinkle comprising stilbene derivative from Vitis vinifera root as effective component | |
KR101764879B1 (en) | Hair growth activating composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |